Company profile: Keros Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical discovery, development, and commercialization of novel treatments.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Keros Therapeutics
Scienture
HQ: United States
Website
- Description: Provider of pharmaceutical research focused on drug screening, with a pipeline including SCN-102 (oral cardiovascular liquid; FDA-accepted NDA), SCN-104 (self-injectable CNS/pain drug-device; advanced development), SCN-107 (long-acting pain injection; formulation optimization with pre-clinical planned), and SCN-106 (early-stage biosimilar; clone selection completed; BIA meeting planned).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scienture company profile →
CervoMed
HQ: United States
Website
- Description: Provider of clinical-stage research and development focused on discovering therapies for brain degenerative illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CervoMed company profile →
Octave Bioscience
HQ: United States
Website
- Description: Provider of biotechnology solutions leveraging precision medicine and scientific insights to treat patients with multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Octave Bioscience company profile →
Oligomerix
HQ: United States
Website
- Description: Provider of target identification and validation technologies to enhance drug discovery for neurodegenerative diseases, and tau-targeting therapeutics including OLX-07010, a Phase 1 small molecule inhibitor of tau self-association, a series of tau small molecule inhibitors, and companion biomarker programs to aid diagnosis and monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oligomerix company profile →
Vallon Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development focused on new medications for central nervous system disorders, including ADAIR, an investigational novel abuse-deterrent formulation of amphetamine immediate release.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vallon Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Keros Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Keros Therapeutics
2.2 - Growth funds investing in similar companies to Keros Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Keros Therapeutics
4.2 - Public trading comparable groups for Keros Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →